Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00607594 · ClinicalTrials.gov registry record · Phase 2
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
A Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Stage IV Gastric Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 5
- Study locations
NCT00607594: Completed Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Stage IV Gastric Cancer, sponsored by National Cancer Institute (NCI).
NCT00607594 is a Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Stage IV Gastric Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 21 participants, below the 89-participant average among 7 other Adenocarcinoma of the Gastroesophageal Junction trials with a reported enrollment target (76% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00607594, a Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Stage IV Gastric Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial is studying how well saracatinib works in treating patients with locally advanced or metastatic stomach or gastroesophageal junction cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. CR is defined as disappearance of all non-target lesions and normalization of tumor marker level.
Conditions Studied
Interventions
- DRUG saracatinib
Study Locations (5)
Ontario
- Juravinski Cancer Centre at Hamilton Health Sciences - Hamilton
- University Health Network-Princess Margaret Hospital - Toronto
Georgia
- Hamilton Medical Center - Dalton
Alberta
- Cross Cancer Institute - Edmonton
Quebec
- McGill University Department of Oncology - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
What the finished NCT00607594 record still lists
NCT00607594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 89-participant average among 7 other Adenocarcinoma of the Gastroesophageal Junction trials with a reported enrollment target (76% lower).
The record links to 7 conditions, with Adenocarcinoma of the Gastroesophageal Junction appearing as the primary indexed condition, and to 1 intervention - of which saracatinib is the first listed.
NCT00607594 lists 5 locations in 4 states (Ontario, Georgia, Alberta).
Frequently Asked Questions
What is clinical trial NCT00607594 about?
NCT00607594 is a clinical study titled "Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer". This phase II trial is studying how well saracatinib works in treating patients with locally advanced or metastatic stomach or gastroesophageal junction cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00607594?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2008-01. Estimated completion is 2012-04.
What conditions does trial NCT00607594 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Gastroesophageal Junction, Stage IV Gastric Cancer, Recurrent Gastric Cancer, Stage III Gastric Cancer, Adenocarcinoma of the Stomach.
What interventions are being tested in trial NCT00607594?
The interventions under investigation include: saracatinib (DRUG).
Who is sponsoring clinical trial NCT00607594?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00607594 being conducted?
This trial has 5 study locations across Georgia, Alberta, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Gastroesophageal Junction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Induction FLOT With CROSS CRT for Esophageal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
COMPLETED · Phase 2
-
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
COMPLETED · Phase 2
-
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
COMPLETED · Phase 2
-
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
COMPLETED · Phase 2
-
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia